* Tandem Diabetes Care Inc TNDM.OQ reported a quarterly
adjusted
loss of 35 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -38 cents. The mean expectation of
twenty analysts for the quarter was for a loss of 41 cents per
share. Wall Street expected results to range from -50 cents
to -27 cents per share.
* Revenue rose 31.4% to $243.97 million from a year ago;
analysts
expected $223.66 million.
* Tandem Diabetes Care Inc's reported EPS for the quarter
was a
loss of 35 cents.
* The company reported a quarterly loss of $23.25 million.
* Tandem Diabetes Care Inc shares had fallen by 21.9% this
quarter and gained 11.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Tandem Diabetes
Care Inc is $56.50
This summary was machine generated from LSEG data November 7 at
04:41 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.41 -0.35 Beat
Jun. 30 2024 -0.54 -0.48 Beat
Mar. 31 2024 -0.76 -0.63 Beat
Dec. 31 2023 -0.25 -0.27 Missed